Jessica Ann Zerillo, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 8 | 2023 | 2346 | 0.900 |
Why?
|
Quality Indicators, Health Care | 3 | 2019 | 1805 | 0.890 |
Why?
|
Medical Errors | 4 | 2024 | 1260 | 0.810 |
Why?
|
Comprehensive Health Care | 1 | 2018 | 123 | 0.590 |
Why?
|
Quality Improvement | 6 | 2024 | 3857 | 0.590 |
Why?
|
Benchmarking | 1 | 2020 | 1057 | 0.440 |
Why?
|
Academic Medical Centers | 3 | 2024 | 2785 | 0.440 |
Why?
|
Anus Neoplasms | 2 | 2024 | 336 | 0.350 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5367 | 0.350 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1444 | 0.320 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6975 | 0.300 |
Why?
|
Neoplasms | 4 | 2020 | 22371 | 0.280 |
Why?
|
Antineoplastic Agents | 4 | 2021 | 13677 | 0.270 |
Why?
|
Administration, Oral | 4 | 2021 | 4034 | 0.250 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2176 | 0.230 |
Why?
|
Terminal Care | 1 | 2015 | 1770 | 0.210 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1640 | 0.200 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8052 | 0.190 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7951 | 0.180 |
Why?
|
Quality of Life | 2 | 2019 | 13490 | 0.170 |
Why?
|
Esophageal Neoplasms | 2 | 2021 | 1668 | 0.170 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 2019 | 49 | 0.170 |
Why?
|
Safety Management | 1 | 2024 | 765 | 0.150 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6395 | 0.140 |
Why?
|
Esophagectomy | 1 | 2021 | 481 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4058 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11878 | 0.140 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7477 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5432 | 0.130 |
Why?
|
Central Venous Pressure | 1 | 2016 | 80 | 0.130 |
Why?
|
Patient Care Planning | 1 | 2020 | 905 | 0.120 |
Why?
|
Patient Care Team | 2 | 2017 | 2523 | 0.120 |
Why?
|
Data Mining | 1 | 2019 | 563 | 0.110 |
Why?
|
Lung Neoplasms | 2 | 2016 | 13586 | 0.110 |
Why?
|
Models, Organizational | 1 | 2017 | 548 | 0.110 |
Why?
|
Mutagenesis, Insertional | 1 | 2016 | 661 | 0.110 |
Why?
|
Delphi Technique | 1 | 2017 | 890 | 0.100 |
Why?
|
Humans | 24 | 2024 | 768171 | 0.100 |
Why?
|
Documentation | 2 | 2019 | 917 | 0.100 |
Why?
|
Hepatectomy | 1 | 2016 | 588 | 0.100 |
Why?
|
Quality of Health Care | 2 | 2018 | 4310 | 0.100 |
Why?
|
Critical Pathways | 1 | 2015 | 476 | 0.090 |
Why?
|
Focus Groups | 1 | 2017 | 1460 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1436 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2507 | 0.090 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3239 | 0.080 |
Why?
|
Survivors | 1 | 2020 | 2381 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2907 | 0.080 |
Why?
|
Monitoring, Intraoperative | 1 | 2016 | 948 | 0.080 |
Why?
|
Quinazolines | 1 | 2016 | 1373 | 0.080 |
Why?
|
Risk Management | 2 | 2023 | 558 | 0.080 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 937 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1397 | 0.080 |
Why?
|
Retrospective Studies | 7 | 2024 | 81760 | 0.080 |
Why?
|
Aged | 10 | 2024 | 171502 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1514 | 0.070 |
Why?
|
Liver Diseases | 1 | 2016 | 1305 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4861 | 0.070 |
Why?
|
Medication Adherence | 1 | 2018 | 2187 | 0.060 |
Why?
|
Massachusetts | 2 | 2017 | 8890 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2021 | 4887 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2016 | 2603 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2337 | 0.060 |
Why?
|
Patient Compliance | 1 | 2015 | 2697 | 0.060 |
Why?
|
Condylomata Acuminata | 1 | 2024 | 79 | 0.060 |
Why?
|
Clinical Competence | 1 | 2018 | 4858 | 0.050 |
Why?
|
United States | 2 | 2024 | 73039 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 6209 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3643 | 0.050 |
Why?
|
Male | 9 | 2024 | 364731 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 4282 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 223487 | 0.040 |
Why?
|
Hospitalization | 1 | 2018 | 10840 | 0.040 |
Why?
|
Female | 9 | 2024 | 397187 | 0.040 |
Why?
|
Internship and Residency | 1 | 2018 | 5953 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5706 | 0.040 |
Why?
|
Health Records, Personal | 1 | 2019 | 127 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17569 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 351 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5863 | 0.040 |
Why?
|
Games, Experimental | 1 | 2016 | 32 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 348 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2017 | 338 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2017 | 59626 | 0.030 |
Why?
|
Risk Assessment | 1 | 2015 | 24318 | 0.030 |
Why?
|
Risk Factors | 2 | 2024 | 74944 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2021 | 65379 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2019 | 2732 | 0.020 |
Why?
|
Fluid Therapy | 1 | 2016 | 587 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2914 | 0.020 |
Why?
|
Adult | 4 | 2024 | 223646 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 939 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7213 | 0.020 |
Why?
|
Internet | 1 | 2021 | 3110 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 951 | 0.020 |
Why?
|
Educational Measurement | 1 | 2016 | 1260 | 0.020 |
Why?
|
Mass Screening | 1 | 2024 | 5458 | 0.020 |
Why?
|
Young Adult | 1 | 2015 | 60066 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6124 | 0.020 |
Why?
|
Teaching | 1 | 2016 | 1171 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8741 | 0.020 |
Why?
|
Ultrasonography | 1 | 2019 | 6004 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54924 | 0.020 |
Why?
|
Software | 1 | 2019 | 4480 | 0.020 |
Why?
|
Curriculum | 1 | 2016 | 3782 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12840 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11244 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14164 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 30009 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39354 | 0.010 |
Why?
|